Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 9/20 | 0.42 |
| ▸ | CES1 | P23141 | 7/20 | 0.41 |
| ▸ | CES2 | O00748 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL28259282 | 0.92 | FAAH (0.54) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL10447938 | 0.88 | FAAH (0.35) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL3794549 | 0.88 | FAAH (0.40) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL15711042 | 0.88 | FAAH (0.46) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL30324569 | 0.88 | FAAH (0.40) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL281599 | 0.88 | FAAH (0.40) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL5402982 | 0.87 | ALDH1A1 (0.55) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL21924385 | 0.85 | FAAH (0.39) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL6909668 | 0.85 | FAAH (0.39) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL27681955 | 0.85 | FAAH (0.39) | FAAHCES1CES2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117007691-A | Method for detecting content of thermosensitive active protein in liquid milk | 上海市质量监督检验技术研究院 | 2023-11-07 | — | — | CN | claimed |
| US-5011777-A | DNA expression construct | ONCOGEN (US) | 1991-04-30 | — | — | US | claimed |
| US-4963485-A | ANTITUMOR AGENTS | ONCOGEN | 1990-10-16 | — | — | US | claimed |
| EP-0210233-A4 | BRAIN DERIVABLE POLYPEPTIDE FACTORS AND ANTIBODIES. | ONCOGEN (US) | 1989-11-07 | — | — | EP | claimed |
| EP-0210233-A1 | BRAIN DERIVABLE POLYPEPTIDE FACTORS AND ANTIBODIES | ONCOGEN (US) | 1987-02-04 | — | — | EP | claimed |
| WO-1986004239-A1 | BRAIN DERIVABLE POLYPEPTIDE FACTORS AND ANTIBODIES | ONCOGEN (US) | 1986-07-31 | — | — | WO | claimed |
| JP-3172183-A | — | — | None | — | — | JP | disclosed |
| US-20240425505-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-12-26 | — | — | US | disclosed |
| US-12110290-B2 | Triazolopyridinyl compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-10-08 | — | — | US | disclosed |
| US-20240109888-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-04 | — | — | US | disclosed |
| CN-117007691-A | Method for detecting content of thermosensitive active protein in liquid milk | 上海市质量监督检验技术研究院 | 2023-11-07 | — | — | CN | disclosed |
| US-11767322-B2 | Triazolopyridinyl compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220204636-A1 | ANTIBODIES AGAINST HUMAN CD38 | GENMAB A/S (DK) | 2022-06-30 | — | — | US | disclosed |
| CN-1859912-A | Inhibitors of Akt activity | SMITHKLINE BEECHAM CORP (US) | 2006-11-08 | — | — | CN | disclosed |
| WO-2004028452-A2 | METHOD FOR PREPARING CRAMBESCIDIN CORE ACID INTERMEDIATES AND THEIR USE FOR PREPARING CRAMBESCIDIN ALKALOID ANALOGS AS THERAPEUTIC AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-04-08 | — | — | WO | disclosed |
| CN-1134539-C | Thrombopoietin | ��Ĭɭ�����ѧ����˾ | 2004-01-14 | — | — | CN | disclosed |
| US-5643566-A | INTERLEUKINS, INTERFERONS, STABILIZERS | CETUS CORPORATION (US) | 1997-07-01 | — | — | US | disclosed |
| CN-1141061-A | Thrombopoietin | GENENTECH INC (US) | 1997-01-22 | — | — | CN | disclosed |
| JP-H03172183-A | BRAIN FACTOR EXPRESSION SYSTEM | ONCOGEN | 1991-07-25 | — | — | JP | disclosed |
| US-4992271-A | Interleukin in aqueous carrier comprising human serum albumin | CETUS CORPORATION (US) | 1991-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204636-A1 | ANTIBODIES AGAINST HUMAN CD38 | CD38, CD22, CD2 | FAAH 3350/4885CES1 3611/4885CES2 2549/4885 |
| US-20240109888-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | RIPK1, RIPK3, RIPK4 | FAAH 3928/4885CES1 2693/4885CES2 4388/4885 |
| US-11767322-B2 | Triazolopyridinyl compounds as kinase inhibitors | RIPK1, RIPK3, RIPK4 | FAAH 3928/4885CES1 2693/4885CES2 4388/4885 |
| US-12110290-B2 | Triazolopyridinyl compounds as kinase inhibitors | RIPK1, RIPK3, RIPK4 | FAAH 3928/4885CES1 2693/4885CES2 4388/4885 |
| US-20240425505-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | RIPK1, RIPK3, RIPK4 | FAAH 3928/4885CES1 2693/4885CES2 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.